一、担保情况概述 北京雪迪龙科技股份有限公司（以下简称"公司"）于 2025 年 3 月 26 日召开 第五届董事会第十八次会议和第五届监事会第十七次会议，审议通过了《关于为全 资子公司申请银行授信额度提供担保的议案》，同意公司为全资子公司北京雪迪龙 环境科技有限公司（以下简称"雪迪龙环境科技"）及其子公司江西雪迪龙科技有 限公司（以下简称"江西雪迪龙"）、郑州尚蜂环境科技有限公司（以下简称"郑 州尚蜂"），北京华准检测技术有限公司（以下简称"华准检测"），北京雪迪龙 信息科技有限公司（以下简称"雪迪龙信息科技"），广州华鑫工程技术有限公司 （以下简称"广州华鑫"），向银行申请银行综合授信额度提供担保，总担保额度 不超过 3,300 万元。上述全资子公司须在各自审议通过的担保额度范围内向银行申 请综合授信。本次担保期限为自本次董事会审议通过之日起一年内有效，具体项目 担保期限以全资子公司与银行签订的相关协议为准。 公司于 2025 年 3 月 26 日召开第五届董事会第十八次会议和第五届监事会第十 七次会议，审议通过了《关于为全资子公司香港雪迪龙及环境能源申请银行授信额 度提供担保的议案》，同意为全资子公司雪 ...

Financial Performance - Revenue for Q3 2025 reached ¥292,214,183.99, an increase of 12.15% compared to the same period last year[5] - Net profit attributable to shareholders was ¥53,396,357.99, representing a significant growth of 101.69% year-on-year[5] - Basic earnings per share increased by 125.00% to ¥0.09, while diluted earnings per share also rose by 125.00% to ¥0.09[5] - The net profit attributable to the parent company increased by 52.10% to ¥115,370,442.34 compared to ¥75,854,090.72 in the previous period[11] - Net profit for the current period was ¥115,626,923.86, up 52.1% from ¥76,011,090.45 in the previous period[28] - Earnings per share increased to ¥0.18 from ¥0.12, indicating improved profitability[29] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,078,368,398.11, reflecting a 1.15% increase from the end of the previous year[5] - Total liabilities increased to ¥474,870,624.01 from ¥456,943,473.73, indicating a rise in financial obligations[25] - The company's equity attributable to shareholders was ¥2,598,239,062.65, up by 0.65% from the previous year[5] - Total equity attributable to shareholders rose to ¥2,598,239,062.65 from ¥2,581,513,781.02, reflecting a stable equity position[25] Cash Flow - Cash flow from operating activities for the year-to-date was ¥155,427,765.39, an increase of 8.77%[5] - Cash flow from operating activities was ¥893,256,391.59, showing a positive trend in cash generation[31] - The net cash flow from operating activities was $155,427,765.39, an increase of 8.5% compared to $142,898,970.13 in the previous period[32] - Total cash outflow from operating activities was $794,437,419.96, down from $811,670,368.26, showing a decrease of 2.1%[32] - The company’s cash flow from operating activities remained stable with a slight decrease in cash outflows, indicating effective cash management strategies[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 49,511[13] - The largest shareholder, Ao Xiaoqiang, holds 57.83% of the shares, totaling 367,660,000 shares[13] - The company repurchased a total of 11,243,157 shares, accounting for 1.77% of the total share capital, with an average price of 5.38 CNY per share[16] - The total amount spent on the share repurchase was 60,512,734.11 CNY, which exceeded the lower limit of the repurchase plan[16] - The company plans to reduce its repurchased shares by up to 6,357,609 shares, representing 1% of the total share capital, within three months starting from August 27, 2025[16] - As of September 30, 2025, the company held 4,885,645 shares from the repurchase account, which is 0.77% of the total share capital[17] Income and Expenses - Total operating revenue for the current period reached ¥888,292,361.18, an increase of 6.4% compared to ¥835,346,354.45 in the previous period[27] - Total operating costs decreased slightly to ¥790,491,868.49 from ¥791,878,496.88, reflecting a cost reduction strategy[27] - The company reported a significant increase in other income to ¥33,270,263.13 from ¥27,407,018.49, contributing positively to overall profitability[28] - Research and development expenses increased to ¥72,222,168.57 from ¥68,941,445.48, highlighting a commitment to innovation[27] Other Financial Metrics - Non-recurring gains and losses for the current period totaled ¥5,046,523.78, down from ¥16,289,842.39 in the previous year[8] - Investment income decreased by 80.10% to ¥2,676,775.95 from ¥13,448,525.77, primarily due to losses from joint ventures and reduced returns from cash management products[11] - The company reported a significant increase in credit impairment losses, rising by 1471.96% to ¥3,276,021.26 due to intensified collection efforts[11] - Deferred income decreased by 84.48% to ¥1,356,248.18, mainly due to the receipt of significant government grants in the previous year[10] - Deferred income tax liabilities rose to ¥660,704.89 from ¥463,280.09, indicating potential future tax obligations[25] Currency and Exchange - The foreign currency translation adjustment showed a dramatic increase of 320.94%, reaching ¥288,913.55 due to exchange rate fluctuations[11] - Other comprehensive income increased by 633.86% to ¥8,032,598.91, attributed to foreign exchange rate changes[11]

Market Overview - On October 23, the environmental equipment sector rose by 0.02% compared to the previous trading day, with Xuedilong leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Xuedilong (002658) closed at 8.85, with a gain of 3.87% and a trading volume of 462,400 shares, amounting to a transaction value of 403 million yuan [1] - Other notable performers included ST Qingyan (301288) with a 3.60% increase, Guolin Technology (300786) up by 3.00%, and Hengying Environmental (603126) rising by 1.29% [1] Capital Flow - The environmental equipment sector experienced a net outflow of 70.02 million yuan from institutional investors, while retail investors saw a net inflow of 46.67 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with retail investors showing interest despite the institutional outflow [2] Individual Stock Capital Flow - Xuedilong saw a net inflow of 27.23 million yuan from institutional investors, while it faced a net outflow of 10.39 million yuan from retail investors [3] - Other stocks like Fida Environmental (600526) and Guolin Technology (300786) also experienced varied capital flows, with institutional and retail investors showing different levels of interest [3]

Core Points - The project for updating and digitizing the equipment of the National Air Quality Monitoring Network's urban stations has a total bid amount of 56.8138 million yuan, with winning bids from Xuedilong, Lihua Technology, and Landun Optoelectronics [1][2]. Bid Information - Project Name: National Air Quality Monitoring Network Urban Station Equipment Update and Digitization Upgrade Project [3]. - Total Bid Amount: 56.8138 million yuan [2]. - Winning Suppliers and Bid Amounts: - Beijing Xuedilong Technology Co., Ltd.: 20.556 million yuan for the first package [3]. - Lihua Technology (Hunan) Co., Ltd.: 24.6078 million yuan for the second package [3]. - Anhui Landun Optoelectronics Co., Ltd.: 11.65 million yuan for the third package [3]. Detailed Breakdown - **First Package (Xuedilong)**: - Total Bid: 20.556 million yuan - Includes SO2, NO2, O3, and CO monitoring equipment [4][5]. - **Second Package (Lihua Technology)**: - Total Bid: 24.6078 million yuan - Includes various gas monitoring equipment with advanced features such as automatic range switching and self-diagnosis capabilities [7][9]. - **Third Package (Landun Optoelectronics)**: - Total Bid: 11.65 million yuan - Includes SO2, NO2, O3, and CO monitoring equipment, along with digitization devices [12].

Core Insights - Mass spectrometry technology is a key common technology in the industry, experiencing strong growth in recent years. Major companies like Xuedilong, Hikvision, and United Imaging are entering the high-end mass spectrometry field, injecting new vitality into a market traditionally dominated by international giants [2][3][4]. Market Overview - The global mass spectrometer market is projected to reach $7.46 billion in sales by 2024, with an expected compound annual growth rate (CAGR) of 6.5%, reaching $10.91 billion by 2031. The Chinese market is also performing well, with a market size of 19.27 billion yuan in 2024, reflecting a year-on-year growth of 15.37%, significantly higher than the global average [3][4]. Domestic Market Dynamics - The high-end mass spectrometry market in China has long been monopolized by international brands, with about 90% of the instruments in use being imported and a domestic production rate of less than 5%. The "14th Five-Year Plan" for medical equipment development emphasizes the need to focus on high-end mass spectrometry equipment and promote self-sufficiency in core technologies [4][5]. Company Developments - Xuedilong, a leader in environmental monitoring, is accelerating its expansion into the high-end mass spectrometry field. The company has established "HuaiZhong Mass Spectrometry" in collaboration with Huairou Hard Technology Innovation Service Co., and has developed a domestically produced time-of-flight mass spectrometer (TOF-MS) with independent intellectual property rights [5][6][9]. - Hikvision, a leader in security, is leveraging its "Hikvision Intelligent Imaging" platform to create a complete product matrix in chromatography and mass spectrometry. The company has introduced innovative products such as the gas chromatography single quadrupole mass spectrometer (GC-MS) AQ3160, which features advanced sensitivity and automation capabilities [10][11]. - United Imaging, a leader in medical imaging, is constructing a global innovation high-end medical equipment manufacturing base, focusing on mass spectrometers and spectrometers. Its subsidiary, Yuezhi Scientific Instruments, is dedicated to the development and application of miniaturized mass spectrometers [12][15]. Industry Trends - The entry of these new players into the mass spectrometry market demonstrates a common characteristic: they possess strong financial resources and mature industrial capabilities, enabling them to rapidly advance infrastructure development and market application expansion. The acceleration of domestic substitution processes, along with ongoing policy and financial support, is forming a complete industrial chain in the domestic mass spectrometry sector [15][16].

Group 1 - Xuedilong plans to invest no more than 400 million yuan to build an innovation industrial base in Changping District, Beijing, focusing on chromatography and mass spectrometry production lines [1] - The project aims to enhance research and production capabilities in carbon monitoring and measurement systems [1] Group 2 - Zejing Pharmaceutical's tri-specific antibody drug ZGGS34 has received clinical trial approval from the National Medical Products Administration for treating MUC17 positive advanced solid tumors [2] - The drug shows strong anti-tumor activity and good safety in preclinical studies [2] Group 3 - Aosaikang's new cMET inhibitor ASK202 will present clinical research data at the 2025 ESMO annual meeting, showing an objective response rate of 68.8% and a disease control rate of 93.8% in advanced non-small cell lung cancer patients [2][3] Group 4 - China Life expects a net profit of 156.785 billion to 177.689 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 50% to 70% [4] Group 5 - Silan Microelectronics plans to jointly invest 5.1 billion yuan to build a 12-inch high-end analog chip production line, with a total project investment of 20 billion yuan [5][6] Group 6 - New City intends to use 156.65 million yuan of remaining fundraising to invest in a "Building Green Energy and Zero Carbon Park" project, with a total investment of 257 million yuan [8] Group 7 - Yidao Information plans to acquire control of Guangzhou Langguo Electronic Technology and Shenzhen Chengwei Information through a combination of share issuance and cash payment [9] Group 8 - Xiling Information's controlling shareholder has received a notice of lifting restrictions, allowing normal business operations to resume [10] Group 9 - Dongpeng Holdings' first batch of rock slab products has passed the highest level 5A quality inspection, becoming one of the first companies to meet the new national standard [11] Group 10 - Aonlikang's levofloxacin tablets have received approval from the National Medical Products Administration, classified as a chemical drug of category 4 [15] Group 11 - Haizheng Pharmaceutical's Taizhou factory has had its GMP non-compliance declaration revoked by the EU, confirming compliance with EU GMP requirements [17][18] Group 12 - Hongfuhan's shareholder plans to reduce its stake by up to 1.5% through various trading methods due to asset integration and funding needs [19] Group 13 - Purang Co. plans to establish a wholly-owned subsidiary in Hong Kong to enhance its international competitiveness and service levels [20] Group 14 - Tianhe Magnetic Materials' subsidiary has signed an investment agreement for a project worth 850 million yuan focused on high-performance rare earth permanent magnets [22] Group 15 - Xiangfenghua reported a 64.64% year-on-year decline in net profit for the first three quarters, despite an 8.16% increase in revenue [23] Group 16 - Darui Electronics reported a 26.84% year-on-year increase in net profit for the first three quarters, with total revenue growing by 28.59% [24] Group 17 - Xiangsheng Medical reported a 4.56% year-on-year decline in net profit for the first three quarters, despite a 41.95% increase in net profit for the third quarter [25]

Core Viewpoint - Multiple companies in the Shanghai and Shenzhen stock markets have announced significant developments, including investments in semiconductor manufacturing, clinical research advancements, and changes in corporate governance, which may present investment opportunities and insights for stakeholders [3]. Investment Announcements - Silan Microelectronics plans to invest 20 billion yuan to establish a 12-inch high-end analog integrated circuit chip manufacturing line, aiming for a production capacity of 54 million chips annually after completion [4]. - Xidilong intends to invest no more than 400 million yuan to purchase land use rights and build an innovation industrial base, adding chromatography and mass spectrometry production lines [8]. - Tianhe Magnetic Materials' subsidiary plans to invest 850 million yuan in high-performance rare earth permanent magnets and component manufacturing [9]. - New City plans to allocate 157 million yuan of remaining fundraising to a green energy and zero-carbon park planning project [10]. - Yanguang Nuohuo proposes to invest 15 million yuan to increase the registered capital of Yuanma Zhiyao, focusing on innovative CAR-T cell therapies [15]. Corporate Governance Changes - Xiling Information's controlling shareholder and general manager has had their detention lifted, allowing them to resume normal duties [5][6]. Regulatory Developments - Haizheng Pharmaceutical's Taizhou factory has had its GMP non-compliance status revoked by the EU, positively impacting its product sales in the EU market [7]. - Zhonghe Titanium White will change its stock name to "Titanium Energy Chemical" starting October 20, 2025, while retaining its stock code [14]. Performance Reports - China Life expects a net profit increase of approximately 50% to 70% for the first three quarters of 2025, estimating profits between 156.785 billion yuan and 177.689 billion yuan [20]. - Yangjie Technology reported a 52.4% increase in net profit for Q3 2025, driven by growth in the semiconductor sector [21]. - Xiangsheng Medical's Q3 net profit grew by 41.95%, despite a decline in revenue [22]. - Zhuhai Guanyu anticipates a net profit increase of 36.88% to 55.54% for the first three quarters of 2025 [23]. - Huiquan Beer reported a 23.7% increase in net profit for Q3 2025 [24]. - Darui Electronics' net profit grew by 26.84% in the first three quarters of 2025 [25]. - Xingwang Yuda turned a profit in Q3 2025, reporting a net profit of 38.3749 million yuan [27]. - Tongyou Technology reported a net profit of 27.6683 million yuan in Q3 2025, marking a turnaround from losses [28]. Shareholding Changes - Hongfuhan's shareholder, Hengmei International, plans to reduce its stake by up to 1.5% [30]. - Intelligent Control's controlling shareholder's associate plans to reduce its stake by up to 1% [31].

Core Viewpoint - The company plans to acquire state-owned land use rights in Beijing to build an innovative industry base, investing up to 400 million yuan, focusing on high-end scientific instruments and carbon monitoring solutions [1][2][3] Group 1: Investment and Project Details - The company intends to invest no more than 400 million yuan in the construction of a new production line for chromatography and mass spectrometry, aligning with the national "dual carbon" strategy [1] - The investment will cover land acquisition, the establishment of a research and development center for instruments, and working capital [1] - The project aims to enhance the company's capabilities in high-end scientific instruments, which are crucial for national scientific research and industrial development [2] Group 2: Strategic Importance - High-end scientific instruments are identified as strategic tools for major national tasks and future industrial development, marking a key area for technological advancement [2] - The company has established a foundation in mass spectrometry technology, with products applicable in various fields such as environmental monitoring, industrial processes, and safety testing [2] - The investment is expected to strengthen the company's market position and support its strategic planning and operational development [3] Group 3: Funding and Impact - The funding for the project will come from the company's own or self-raised funds, ensuring no disruption to existing business operations [3] - The implementation of the investment project is anticipated to attract and cultivate professional talent, enhancing the company's research and innovation capabilities [3] - The project is not expected to significantly impact the company's operating performance in 2025 [3]

Core Points - The company, Xuedilong (002658.SZ), has approved a proposal to purchase land use rights and invest in the construction of an innovative industrial base project, with a budget not exceeding RMB 400 million [1] - The project will include the addition of chromatography and mass spectrometry production lines, aligning with the national "dual carbon" strategy to develop carbon monitoring and measurement systems [1] - The investment will be allocated for land use rights acquisition, the establishment of a research and development center for instruments and meters, production line construction, and working capital [1] - This initiative is in line with the company's overall business layout and long-term development strategy, aimed at consolidating its leading market position in the industry and laying a solid foundation for future growth [1] - The management has been authorized to handle matters related to land acquisition, agreement signing, project construction, and environmental assessments [1]

Core Viewpoint - The company, Xuedilong (002658.SZ), has approved a proposal to purchase land use rights and invest in the construction of an innovative industrial base, aligning with national "dual carbon" strategies and enhancing its market position [1] Investment Details - The company plans to invest up to RMB 400 million (approximately $56 million) using its own or self-raised funds for the land purchase and project development [1] - The investment will include the establishment of new production lines for chromatography and mass spectrometry, as well as carbon monitoring and measurement systems [1] Strategic Alignment - The project is in line with the company's overall business layout and long-term development strategy, aimed at consolidating its leading market position in the industry [1] - The investment is expected to lay a solid foundation for the company's next phase of rapid growth [1] Management Authorization - The company's management has been authorized to handle matters related to land acquisition, agreement signing, project construction, and environmental assessments [1]